Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy COTY?
Source: Globenewswire
- Soleno Stock Decline: Following a report from Scorpion Capital labeling Soleno Therapeutics' Vykat XR as overpriced and potentially unsafe for children, the stock plummeted by 7.41% to close at $71.63 on August 15, 2025, indicating significant market concerns regarding product safety.
- Avita Financial Struggles: Avita Medical revealed a backlog of unpaid claims affecting demand for its Recell product in its Q2 2025 report, leading to a 21% drop in stock price to $4.25 on August 8, 2025, highlighting major challenges in medical claims management.
- Coty's Disappointing Performance: Coty reported an unexpected loss and provided disappointing guidance for FY 2025, resulting in a 21.6% decline in stock price to $3.81 on August 21, 2025, reflecting broader market challenges and shifts in consumer behavior impacting sales.
- Legal Investigation Impact: Bragar Eagel & Squire is investigating potential federal securities law violations by these three companies, which could lead to further legal and financial repercussions, necessitating investor vigilance regarding future developments to assess potential risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COTY
Wall Street analysts forecast COTY stock price to rise
12 Analyst Rating
1 Buy
9 Hold
2 Sell
Hold
Current: 2.470
Low
2.50
Averages
4.30
High
10.00
Current: 2.470
Low
2.50
Averages
4.30
High
10.00
About COTY
Coty Inc. is a beauty company with a portfolio of brands across fragrance, color cosmetics, and skin and body care. The Company has a diverse portfolio of brands, which includes both owned and licensed. Its brand portfolio is classified into two segments: Consumer beauty and Prestige. The consumer beauty brands include Adidas, Beckham, Bozzano, Bourjois, Bruno Banani, CoverGirl, Jovan, Mexx, LeGer by Lena Gercke, Monange, Nautica, Paixao, Rimmel, Risque, Sally Hansen, and Vera Wang. Its prestige brands include Burberry, Calvin Klein, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Kylie Cosmetics by Kylie Jenner, Lancaster, Marc Jacobs, Miu Miu, Orveda, and Tiffany & Co. Its mass beauty brands are primarily sold through hypermarkets, supermarkets, drug stores and pharmacies, mid-tier department stores, traditional food and drug retailers, and dedicated e-commerce retailers. It markets, sells and distributes its products in over 120 countries and territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coty Under Investigation, Stock Plummets 15.56%
- Poor Financial Performance: Coty reported non-GAAP earnings per share of $0.14 for Q2 FY2026, missing consensus estimates by $0.04, indicating a decline in profitability that may undermine investor confidence.
- Withdrawal of Full-Year Guidance: The company withdrew its full-year 2026 guidance and introduced a turnaround strategy focused on core brands, which could impact future market performance and investor expectations.
- Significant Stock Decline: Following the earnings report, Coty's stock price fell by $0.49, or 15.56%, closing at $2.66 per share on February 6, 2026, reflecting market concerns about the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Coty and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal risks and financial losses, affecting the company's reputation and shareholder interests.
See More
Coty Inc. Price Target Cut to $2.50 by Canaccord
- Price Target Adjustment: Morgan Stanley lowered Coty Inc.'s price target from $4.25 to $3.50 while maintaining an Equal Weight rating, reflecting concerns over the company's Q2 performance, which was slightly below expectations, indicating market apprehension about future prospects.
- Poor Guidance: Coty Inc.'s Q3 EBITDA guidance fell significantly short of consensus estimates, with Morgan Stanley highlighting the withdrawal of fiscal 2026 guidance as a key negative factor, suggesting a lack of visibility that could undermine investor confidence moving forward.
- Leadership Transition Impact: Canaccord Genuity also reduced Coty's price target from $3.50 to $2.50, citing uncertainty surrounding the leadership transition and ongoing negative sales growth as critical reasons for the downgrade, which may diminish the company's competitive edge in the market.
- Investment Potential Analysis: While Coty is viewed as a potential investment, analysts suggest that certain AI stocks present greater upside potential and lower downside risk, indicating that investors should exercise caution in their selection process.
See More
Coty Reports $126.9 Million Net Loss in Q2 2026
- Earnings Miss: Coty reported a net loss of $126.9 million for Q2 2026, with non-GAAP EPS of $0.14, falling short of the $0.18 consensus estimate, leading to a 15% drop in after-hours trading and a 52-week low of $2.66, indicating severe underperformance relative to expectations.
- Industry Comparison: The loss is particularly notable against a backdrop of resilient demand in the global beauty and personal care sector, where peers like Estée Lauder and L'Oréal reported stable or improving margins, highlighting Coty's significant performance gap.
- Revenue Decline: Coty's like-for-like revenue fell approximately 3%, contrasting sharply with prior guidance of low-single-digit growth, suggesting a weakening competitive position that could impact future market share.
- Strategic Shift: The company withdrew its full-year FY 2026 guidance and introduced a new
See More
Coty Reports $126.9 Million Loss in Q2 2026
- Significant Financial Loss: Coty reported a net loss of $126.9 million for Q2 FY 2026, with non-GAAP EPS of $0.14, falling short of the $0.18 consensus estimate, leading to a 15% drop in after-hours trading and hitting a 52-week low.
- Industry Comparison Discrepancy: In a global beauty and personal care sector that has generally shown resilient demand, Coty's losses stand out, as peers like Estée Lauder and L'Oréal reported stable or improving margins in their latest quarters.
- Declining Revenue Trend: The company's like-for-like revenue declined approximately 3%, contrasting sharply with prior guidance of low-single-digit growth, indicating a significant gap between internal performance and public expectations, marking one of the widest earnings misses in the mid-cap consumer sector.
- Strategic Shift and Uncertain Outlook: Coty withdrew its full-year FY 2026 guidance and introduced a new
See More
Calvin Klein Launches New Fragrance Line Featuring Rosalía
- Brand Ambassador: Global superstar ROSALÍA has been appointed as the face of Calvin Klein's new fragrance line, euphoria elixirs, aiming to leverage her influence to attract younger consumers and enhance brand image.
- Product Launch: The euphoria elixirs collection features three distinct parfum intense creations, showcasing the brand's innovation in the fragrance market and expected to appeal to consumers seeking high-end scents.
- Market Strategy: By collaborating with a renowned artist, Calvin Klein aims to strengthen its position in the competitive fragrance market while expanding its reach through ROSALÍA's fan base.
- Brand Synergy: This partnership not only elevates Calvin Klein's brand visibility but may also drive sales growth for Coty Inc., further solidifying its market share in the fragrance industry.
See More
Calvin Klein Launches New Euphoria Elixirs Fragrance Collection
- New Fragrance Launch: Calvin Klein, in collaboration with Coty, unveils the euphoria elixirs collection featuring three distinct fragrances—magnetic, bold, and solar elixir—designed to express confidence and allure, targeting a younger consumer demographic.
- Innovative Concentration: Each fragrance boasts an ultra-concentration of 28% or more, representing the highest fragrance concentration for Calvin Klein Fragrances, which enhances the brand's competitiveness in the premium fragrance market and may boost brand image and market share.
- Celebrity Endorsement Impact: Global superstar ROSALÍA serves as the face of the campaign, leveraging her influence and artistic expression to enhance brand appeal, which is expected to drive sales growth significantly.
- Market Pricing Strategy: The euphoria elixirs collection is priced at $129 for 100ml, $99 for 50ml, $79 for 30ml, and $36 for 10ml, with a strategic pricing range that aims to attract customers across various spending tiers.
See More
Coty Under Investigation, Stock Plummets 15.56%
- Poor Financial Performance: Coty reported non-GAAP earnings per share of $0.14 for Q2 FY2026, missing consensus estimates by $0.04, indicating a decline in profitability that may undermine investor confidence.
- Withdrawal of Full-Year Guidance: The company withdrew its full-year 2026 guidance and introduced a turnaround strategy focused on core brands, which could impact future market performance and investor expectations.
- Significant Stock Decline: Following the earnings report, Coty's stock price fell by $0.49, or 15.56%, closing at $2.66 per share on February 6, 2026, reflecting market concerns about the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Coty and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal risks and financial losses, affecting the company's reputation and shareholder interests.
See More
Coty Inc. Price Target Cut to $2.50 by Canaccord
- Price Target Adjustment: Morgan Stanley lowered Coty Inc.'s price target from $4.25 to $3.50 while maintaining an Equal Weight rating, reflecting concerns over the company's Q2 performance, which was slightly below expectations, indicating market apprehension about future prospects.
- Poor Guidance: Coty Inc.'s Q3 EBITDA guidance fell significantly short of consensus estimates, with Morgan Stanley highlighting the withdrawal of fiscal 2026 guidance as a key negative factor, suggesting a lack of visibility that could undermine investor confidence moving forward.
- Leadership Transition Impact: Canaccord Genuity also reduced Coty's price target from $3.50 to $2.50, citing uncertainty surrounding the leadership transition and ongoing negative sales growth as critical reasons for the downgrade, which may diminish the company's competitive edge in the market.
- Investment Potential Analysis: While Coty is viewed as a potential investment, analysts suggest that certain AI stocks present greater upside potential and lower downside risk, indicating that investors should exercise caution in their selection process.
See More
Coty Reports $126.9 Million Net Loss in Q2 2026
- Earnings Miss: Coty reported a net loss of $126.9 million for Q2 2026, with non-GAAP EPS of $0.14, falling short of the $0.18 consensus estimate, leading to a 15% drop in after-hours trading and a 52-week low of $2.66, indicating severe underperformance relative to expectations.
- Industry Comparison: The loss is particularly notable against a backdrop of resilient demand in the global beauty and personal care sector, where peers like Estée Lauder and L'Oréal reported stable or improving margins, highlighting Coty's significant performance gap.
- Revenue Decline: Coty's like-for-like revenue fell approximately 3%, contrasting sharply with prior guidance of low-single-digit growth, suggesting a weakening competitive position that could impact future market share.
- Strategic Shift: The company withdrew its full-year FY 2026 guidance and introduced a new
See More
Coty Reports $126.9 Million Loss in Q2 2026
- Significant Financial Loss: Coty reported a net loss of $126.9 million for Q2 FY 2026, with non-GAAP EPS of $0.14, falling short of the $0.18 consensus estimate, leading to a 15% drop in after-hours trading and hitting a 52-week low.
- Industry Comparison Discrepancy: In a global beauty and personal care sector that has generally shown resilient demand, Coty's losses stand out, as peers like Estée Lauder and L'Oréal reported stable or improving margins in their latest quarters.
- Declining Revenue Trend: The company's like-for-like revenue declined approximately 3%, contrasting sharply with prior guidance of low-single-digit growth, indicating a significant gap between internal performance and public expectations, marking one of the widest earnings misses in the mid-cap consumer sector.
- Strategic Shift and Uncertain Outlook: Coty withdrew its full-year FY 2026 guidance and introduced a new
See More
Calvin Klein Launches New Fragrance Line Featuring Rosalía
- Brand Ambassador: Global superstar ROSALÍA has been appointed as the face of Calvin Klein's new fragrance line, euphoria elixirs, aiming to leverage her influence to attract younger consumers and enhance brand image.
- Product Launch: The euphoria elixirs collection features three distinct parfum intense creations, showcasing the brand's innovation in the fragrance market and expected to appeal to consumers seeking high-end scents.
- Market Strategy: By collaborating with a renowned artist, Calvin Klein aims to strengthen its position in the competitive fragrance market while expanding its reach through ROSALÍA's fan base.
- Brand Synergy: This partnership not only elevates Calvin Klein's brand visibility but may also drive sales growth for Coty Inc., further solidifying its market share in the fragrance industry.
See More
Calvin Klein Launches New Euphoria Elixirs Fragrance Collection
- New Fragrance Launch: Calvin Klein, in collaboration with Coty, unveils the euphoria elixirs collection featuring three distinct fragrances—magnetic, bold, and solar elixir—designed to express confidence and allure, targeting a younger consumer demographic.
- Innovative Concentration: Each fragrance boasts an ultra-concentration of 28% or more, representing the highest fragrance concentration for Calvin Klein Fragrances, which enhances the brand's competitiveness in the premium fragrance market and may boost brand image and market share.
- Celebrity Endorsement Impact: Global superstar ROSALÍA serves as the face of the campaign, leveraging her influence and artistic expression to enhance brand appeal, which is expected to drive sales growth significantly.
- Market Pricing Strategy: The euphoria elixirs collection is priced at $129 for 100ml, $99 for 50ml, $79 for 30ml, and $36 for 10ml, with a strategic pricing range that aims to attract customers across various spending tiers.
See More
